Introduction
Zygomycosis is an invasive fungal infection which is primarily caused by fungi belonging to the Mucoraceae family. As in other invasive fungal diseases, impairment of the immune system is the most important predisposing factor. Many different organisms have been isolated from patients with zygomycosis, including Absidia corymbifera, Cunninghamella bertholletiae, Rhizonntcor pusillus and Saksenaea vasiformis, but the most common organism causing zygomycosis is Rhizopus arrhizus [1] .
Rhinocerebral infection is the most frequent clinical manifestation of zygomycosis, whereas pulmonary, gastrointestinal, disseminated and cutaneous disease are less common. Patients at risk usually have compromised defence mechanisms, mainly caused by diabetes mellitus, hematological diseases like leukemia or lymphoma, i.v. drug abuse or cytotoxic therapy [2] , although there are reports of zygomycosis in otherwise healthy patients [3] . Histologically, blood vessel invasion with hyphal elements is seen, leading to thrombosis, hemorrhage and tissue necrosis and causing local destruction of the affected organ. The clinical hallmark of the infection is the rapid onset of fever, pain and necrosis. Without early treatment, vascular dissemination is inevitable, leading to death within days [4] . In leukemia patients, zygomycosis usually leads to a delay or interruption of anti-leukemic therapy, thus increasing mortality not only through the fungal infection itself, but also from the inability to adequately treat the hematologic disease.
We describe a case of a 28-year-old patient with acute lymphoblastic leukemia who was found to have aquired rhinocerebral zygomycosis during the inital phase of induction chemotherapy, and who was simultaneously treated aggressively for both, fungal infection and leukemia.
Case report
In July 1997, a 28-year-old male patient was admitted to a general hospital with suspected acute leukemia. About four weeks before admission, the patient experienced a rapidly progressing fatigue, which prevented him from doing his job as an electrician. A few days before admission he noticed multiple bruises on the extremities, which had obviously occurred spontaneously. He had no history of diabetes, immunosuppression or i.v. drug abuse.
On admission, physical examination showed a pale colour of the skin and visible mucous membranes and multiple small hematomas all over the body surface. Body temperature was 36 °C, there were no enlarged lymph nodes palpable, the liver was about 3 cm below the costal margin and the spleen was palpable after deep inspiration. Cardiopulmonary and neurological status was normal.
Laboratory findings showed a leukocytosis with WBC 24,000/mm 3 , platelets 32,000/mm 3 and hemoglobin 9.7 g/dl. A differential blood count yielded 97% leukemic blasts. Serum creatinine was 0.9 mg/dl with a creatinine clearance rate of 120 ml/min. Serum glucose level was 88 mg/dl on admission. Transaminases, gammaglutamyltranspeptidase and alkaline phosphatase were increased, suggesting leukemic infiltration of the liver. Lactic dehydrogenase also showed a marked increase with 594 U/l. A bone marrow examination was done on the day of admission, showing a 95% infiltration with lymphoblasts ( Figure 1 ), which were immunologically characterized as common-ALL of pre-B-phenotype (CDI0+, CD19+, CD34+, HLA-DR+, TdT+). A cytogenetic examination showed a normal male karyotype (46,XY) in 14 metaphases, finally classifying the patient as standard risk.
Five days after admission, chemotherapy was started according to the standard risk protocol of the German Multicenter ALL Study Group, consisting of vincristine, daunorubicin, prednisone, asparaginase and intrathecal administration of methotrexate. One week after chemotherapy start, the patient complained of right-sided facial pain, which was initially treated with paracetamol. An X-ray of the sinuses was done, showing no radiologic signs of sinusitis. During the following days the pain deteriorated, necessitating treatment with opioids. Three days later, the patient located the pain to the right fronto-orbital region and noticed a blurred vision on the right eye. Despite increasing doses of opioids, the headache rapidly worsened and fever (39 °C) occurred on day 13 of chemotherapy. At that time, the peripheral blood showed a leukocyte count of 200/mm 3 and C-reactive protein showed a marked increase to 11.4 mg/dl. Serologic examination showed IgG titers for Aspergillus species, Candida albicans and several viruses within the normal range, with IgM titers being negative. Blood samples were taken for microbiologic examination and the patient was then empirically treated with imipenem and oral itraconazole. A CT scan of the orbitae and paranasal sinuses showed a subtotal opacification of the right maxillary and ethmoidal sinuses, without any radiologic signs of bone destruction or invasion of the orbitae or intracerebral structures. X-ray of the lungs showed no pulmonary infiltrate. An ENT examination was immediately done, showing signs of acute inflammation of the nasal mucous membranes. An opthalmologic examination was normal. The diagnosis of acute sinusitis was made and the antibiotic therapy was combined with local anti-congestive therapy and inhalation. An invasive approach to obtain material for microbiologic examination was denied due to the risk of bleeding with platelets being less than 20,000/mm 3 . After initiation of antibiotic therapy, fever did resolve within 24 hours. On the following day, coagulase-negative staphylococci were isolated from the blood, which were covered by the initial antibiotics. However, two days later, temperature again rose to 39 °C, together with a continiuous deterioration of the pain and further impairment of the vision of the right eye. Vancomycin and fluconazole were added to the antibiotic regimen. On day 20 of chemotherapy, a periorbital edema and proptosis of the right eye was noticed, which progressed rapidly and finally led to a necrosis of the lower lid. At that time, the patient's right-sided vision further decreased, only allowing him to distinguish between bright and dark. A CTscan of the orbitae and the paranasal sinuses was repeated, now showing a progressive opacification of the maxillary and ethmoidal sinuses, and spreading of the inflammatory process to the right orbit (Figure 2 ), leading to a partial destruction of the right eye. Again, no radiologic signs of intracerebral infiltration were seen. An ENT examination was repeated and a decision was made to fenestrate the right maxillary sinus to obtain material for a proper microbiologic diagnosis. The clinical hypothesis at that time was that of mycotic sinusitis spreading to the right orbit and destructing the intraorbital structures. Biopsy from the mucosa of the right maxillary sinus showed brownish necrotic material and broad, non-septate hyphal elements with right-angled branching on histologic examination (Figure 3 ). Antimycotic treatment with amphotericin B and flucytosine was started on day 24, and the anti-leukemic therapy was discontinued. Amphotericin B was badly tolerated by the patient, with chills, nausea, vomiting and severe hypotension, making treatment with intravenous fluids and catecholamines necessary. Because of these side-effects, amphotericin B was given at a reduced dose of 0.5 mg/kg for three days and was finally discontinued, leaving fluconazole as the only antimycotic treatment. Culture of the resected material was done, yielding moulds as causing agents. After Rhizopus arrhizus was identified, the final diagnosis of rhinocerebral zygomycosis was made, and the patient was then transfered to our hospital on day 31.
On day 32, a right radical sphenoethmoidectomy, a partial resection of the right frontal sinus, a subtotal resection of the nasal septum and an orbital exenteration were done (Figure 4) . Immediately after the surgical debridement, fever resolved and two days later, analgesics could be dropped. Postoperatively, treatment with amphotericin B was given at a dose of 1.2 mg/kg/d. Again, antimycotic treatment was badly tolerated and nephrotoxicity was seen with an increase of serum creatinine to 3.0 mg/dl. Antimycotic therapy was then changed to liposomal amphotericin B (Ambisome®), which was adminstered at a dose of 3.5 mg/kg/d for a total of 40 days (cumulative dose of 12,000 mg). Concomitantly, the right orbit was tamponed weekly with compresses, soaked in amphotericin B solution. Induction therapy was continued three weeks after surgery while the patient was in continuous complete remission. During the following anti-leukemic therapy, drugs were administered without dose reduction and delay in time. After finishing the second part of induction chemotherapy, liposomal amphotericin B was discontinued and substituted for oral itraconazole, which was continually given during consolidation therapy. About 4 months later, a leukemic relapse occurred and the patient was then treated with high-dose cytosine arabinoside and mitoxantrone. Unfortunately, a second complete remission could not be achieved by the salvage regimen, leading to the patient's death about four months later. During the whole time period of intensive chemotherapy, there were no signs or symptoms of recurrent mycotic infection. 
Discussion
Invasive fungal infections caused by yeasts and moulds are frequent problems in hematologic patients. Among moulds, Aspergillus species are the most common organisms causing invasive fungal infections, whereas infections with Zygomycetes species are less frequent. Zygomycete infections encompass a broad spectrum of diseases which are caused by fungi of the orders Mucorales and Entomophthorales. In general, severe invasive infections are caused by Mucorales species, while the Entomophthorales species usually cause non-invasive infection of nasal mucosa and subcutaneous tissues. Infections with the Zygomycetes are worldwide in distribution. As in the case of aspergillosis, infections with Zygomycetes are usually aquired by inhalation of spores released into the air from soil or decomposing organic matter [5] , but infections of the skin or subcutaneous tissue in patients with burns, trauma, or intravenous catheters through direct contact have been described in the literature [16, [20] [21] [22] . Vascular invasion is a hallmark of the causal organisms of zygomycosis [6] , leading to thrombosis, infarction and necrosis of the affected tissues [7] . The most common form of zygomycosis is rhinocerebral infection, which usually has been reported in patients with poorly controlled diabetes mellitus [8] [9] [10] [11] and hematologic diseases [12] [13] [14] , and which frequently offers a devastating prognosis in untreated patients. In a recently published review of 123 patients, more than two thirds of the patients with intracranial fungal spread eventually showed a fatal course [15] , although the introduction of amphotericin B as antimycotic treatment has somewhat decreased mortality [3, 9] .
We have described a typical case, demonstrating the clinical course of rhinocerebral zygomycosis in a leukemic patient. The paranasal sinuses have already been colonized by spores inhaled earlier, when the patient finally developed clinically overt acute leukemia. After initiating chemotherapy with complete breakdown of the cellular immune system and impairment of local barriers, invasive infection rapidly developed. As described by others, initial symptoms of rhinocerebral zygomycosis are progressive headaches, fever and fronto-orbital pain. In our patient, right-sided facial pain was the first symptom. It deteriorated despite analgetic treatment, and was followed by the onset of fever which did not adequately respond to treatment with broad-spectrum antibiotics. At that time, clinical as well as radiologic diagnosis of sinusitis was evident, but no invasive approach to identify the causal organism was undertaken. Instead, antibiotic therapy was extended, but this was not effective in terms of clinical improvement, finally leading to intractable pain and near blindness within days.
When reviewing the events happening during the first three weeks of chemotherapy, one could criticize that (1) no early invasive diagnostic approach was undertaken to elucidate the etiological factors leading to this constantly deteriorating parasinusoidal and intraorbital process, and (2) that despite persistent fever in the face of broad-spectrum antibiotics, no intravenous broadspectrum antimycotic treatment with amphotericin B was administered. Finally, (3) when treatment with amphotericin B was initiated after confirming diagnosis of invasive mycosis, infusion-related side-effects were severe with poor tolerability by the patient, leading to dose reduction and finally abandonment of further amphotericin B treatment. At this time, intravenous fluconazole was the only antimycotic therapy, which is ineffective in the case of a Zygomycete infection.
What could be learned from this retrospective analysis is, that aggressive approaches to attain histopathologic diagnosis and microscopic and cultural identification of pathogenetic genera and species in a case of suspected rhinocerebral zygomycosis are not only justified but inevitable [4, 12, 13, 18, 19] . Histopathologically, blood vessels at the infected site are filled with ribbonlike, filamentous, non-septate hyphal elements, about 10 to 25 urn in diameter, showing irregular, right-angled branching, vessel wall infiltration and extension into surrounding tissues. In culture, most species show a rapid growth with coverage of the surface of a petri dish within 24 hours [5] . Secondly, when an invasive fungal infection is suspected, treatment with amphotericin B should be immediately started, using doses of 1.0 to 1.5 mg per kilogram body weight per day, without waiting for the results of fungal cultures [4] . Treatment should be continued for a minimum of 14 days, and total doses of 2,500 to 4,000 mg may be necessary [3, 4] . When toxic side-effects of amphotericin B are intolerable, less toxic but equally or even more effective alternatives have to be chosen. There are several reports demonstrating effective therapy with liposomal amphotericin B with doses between 1 mg/kg per day and 4 mg/kg per day and cumulative doses of 12,000 mg or more with only minor toxicity [11-14, 16,17] . In our patient, liposomal amphotericin B (Ambisome®) was administered at a dose of 3.5 mg/kg per day with a cumulative dose of 12,000 mg. Thirdly, when clinical signs and symptoms of invasive zygomycosis are present or zygomycosis is already proven through histologic or cultural examination of biopsy material, aggressive surgical debridement to remove infected and necrotic tissue has to be undertaken whenever possible [1, 4] . Finally, every effort should be made to control the underlying disease. In our patient, antileukemic therapy was stopped after 75% of the first part of induction treatment and was interrupted for four weeks until the second part of induction chemotherapy was administered. At that time, a stable cytological complete remission was achieved. After resuming chemotherapy, no further dose reduction or break occurred, and the patient was kept to the chemotherapy protocol without delay. Of course one could speculate, that the four-week break of the initial chemotherapy might be at least a partial explanation for the early relapse. On the other hand, it is always difficult to decide when to continue intensive chemotherapy in a patient, who has just survived a life-threatening infection.
